Lixte Biotechnology

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$1.55-$4.42
Market Cap
$4.8M
Shares Short
31,162

Financials

See more
Revenue (12 Mos)
$0
Revenue Growth (YoY)
0%
Gross Profit (12 Mos)
$0
Diluted EPS
-$1.72

News

See more

Yahoo Finance • 12 months ago

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Yahoo Finance • last year

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Yahoo Finance • last year

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Yahoo Finance • 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

About

CEO
Mr. Bastiaan van der Baan M.Sc.
CFO
Mr. Robert Neal Weingarten
Address
680 East Colorado Boulevard, Pasadena, CA, United States, 91101
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
3